Pharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED) (PhA-SLED)

Universitätsklinikum Hamburg-Eppendorf

Status: Completed

Conditions: Replacement Therapy, Renal

Treatments: Other: Pharmacokinetic Analysis

Study type: Observational

Funder types: Other

Identifiers

NCT02287493

PV4244

Details and patient eligibility

About

In a prospective, non-interventional, monocentric observational study the pharmacokinetic properties of selected antiinfective drugs during sustained low-efficiency dialysis (SLED) will be analyzed.

Full description

Antibiotic concentrations are measured whilst patients receive SLED for renal replacement therapy. The plasma specimens will be quantified using high Performance liquid chromatography (HPLC).

Primary endpoint:

• Plasma levels of antiinfectives during SLED

Secondary endpoints:

• mortality
• length of stay at the intensive care unit (ICU) and hospital
• clinical cure of infections

Inclusion criteria:

• age: > 18 years
• patients under SLED
• antiinfective treatment

exclusion criteria:

• missing informed consent

Enrollment: 35 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age: 18 or older
• patients receiving SLED and either meropenem or ceftazidim

Exclusion criteria

• missing informed consent

Trial design

35 participants in 2 patient groups

Meropenem

Description:

Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.

Treatment:

Other: Pharmacokinetic Analysis

Ceftazidim

Description:

Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.

Treatment:

Other: Pharmacokinetic Analysis